Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
Global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach USD 13,385.56 million by 2030 from USD 7,675.00 million in 2022, growing at a CAGR of 7.2% during the forecast period from 2023 to 2030.
Market Segmentation
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Dignosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management and Pancreatic Enzyme Replacement Therapy (PERT), and Others), Drugs Type (Branded and Generic), End User (Specialty Clinics, Hospitals, Diagnostic Center, Homecare, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others), Industry Trends and Forecast to 2030.
Overview of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics:
Driver
• Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis
Restraint
• Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector
Opportunity
• Increasing prevalence of pancreatic disorders and associated conditions
Market Players
Some of the key market players operating in the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are listed below:
• EagleBio
• AbbVie.
• Digestive Care, Inc.
• Nordmark Arzneimittel GmbH & Co.
• Cilian AG
• Alcresta Therapeutics, Inc.
• ChiRhoClin
• Bioserv Diagnostics
• Laboratory Corporation of America
• Organon group of companies
• Metagenics LLC
• Janssen
• Nestlé.
• VIVUS LLC.
• ScheBo Biotech AG
• Abbott.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Product Type Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market Testing Type Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestel Analysis
- 4.2 Porter Analysis
- 5 Industry Insights
- 6 Regulatory Framework
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Increasing Prevalence Of Exocrine Pancreatic Insufficiency (Epi) Due To Chronic Pancreatitis And Cystic Fibrosis
- 7.1.2 Rising Technological Advancements In Diagnosis And Treatment Of Epi
- 7.1.3 Strategic Initiatives By The Key Market Players
- 7.1.4 Sedentary Lifestyles And Unhealthy Diets
- 7.2 Restraints
- 7.2.1 Stringent Regulations To Hamper The Exocrine Pancreatic Insufficiency(Epi) Therapeutic And Diagnostic Sector
- 7.2.2 Side Effects And Religious Hurdles Associated With Pancreatic Enzyme Replacement Therapy (Pert)
- 7.3 Opportunities
- 7.3.1 Increasing Prevalence Of Pancreatic Disorders And Associated Condition
- 7.3.2 Rising Awareness About The Benefits Of Early Diagnosis And Treatment Of Epi
- 7.3.3 Growing Demand For Combination Therapies And Personalized Medicine
- 7.4 Challenges
- 7.4.1 High Cost Associated With Epi Diagnosis And Treatment
- 7.4.2 Limited Availability Of Epi Therapeutics And Diagnostics
- 8 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By Treatment
- 8.1 Overview
- 8.2 Pancreatic Enzyme Replacement Therapy (Pert)
- 8.2.1 By Enzyme
- 8.2.1.1 Lipase
- 8.2.1.2 Protease
- 8.2.1.3 Amylase
- 8.2.2 By Route Of Administration
- 8.2.2.1 Oral
- 8.2.2.1.1 Capsules
- 8.2.2.1.2 Tablets
- 8.2.2.1.3 Powder
- 8.2.2.2 Intravenous
- 8.3 Nutritional Management
- 8.3.1 Vitamin D
- 8.3.2 Vitamin E
- 8.3.3 Vitamin A
- 8.3.4 Vitamin K
- 8.3.5 Others
- 9 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By Diagnosis
- 9.1 Overview
- 9.2 Pancreatic Function Test
- 9.2.1 Stool
- 9.2.1.1 Fecal Elastase Test
- 9.2.1.2 Fecal Fat Test
- 9.2.2 Secretin Pancreatic Function Test
- 9.2.3 Blood Tests
- 9.2.4 C-mixed Triglycerides Breath Test
- 9.2.5 Fasting Plasma Glucose Test
- 9.3 Imaging Test
- 9.3.1 Ct Scanning
- 9.3.2 Magnetic Resonance Imaging Tests (Mri)
- 9.3.3 Endoscopic Retrograde Pancreatography
- 9.3.4 Endoscopic Ultra-sonography (Eus)
- 9.3.5 Secretin-stimulated Magnetic Resonance Cholangiopancreatography
- 10 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By Drug Type
- 10.1 Overview
- 10.2 Branded
- 10.2.1 Creon
- 10.2.2 Zenpep
- 10.2.3 Pancreaze
- 10.2.4 Nutrizym
- 10.2.5 Pancrease Mt
- 10.2.6 Pancrex
- 10.2.7 Cotazym
- 10.2.8 Ultersa
- 10.2.9 Viokace
- 10.2.10 Pertzye
- 10.2.11 Others
- 10.3 Generic
- 11 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By End User
- 11.1 Overview
- 11.2 Hospitals
- 11.2.1 Private
- 11.2.2 Public
- 11.3 Specialty Clinics
- 11.4 Diagnostic Center
- 11.5 Homecare
- 11.6 Research And Academic Institutes
- 11.7 Others
- 12 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By Distribution Channel
- 12.1 Overview
- 12.2 Direct Tender
- 12.3 Retail Pharmacy
- 12.4 Third Party Distributors
- 12.5 Others
- 13 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market, By Region
- 13.1 Overview
- 13.2 North America
- 13.2.1 U.S.
- 13.2.2 Canada
- 13.2.3 Mexico
- 13.3 Europe
- 13.3.1 Germany
- 13.3.2 France
- 13.3.3 U.K.
- 13.3.4 Italy
- 13.3.5 Spain
- 13.3.6 Russia
- 13.3.7 Turkey
- 13.3.8 Belgium
- 13.3.9 Denmark
- 13.3.10 Netherlands
- 13.3.11 Switzerland
- 13.3.12 Sweden
- 13.3.13 Poland
- 13.3.14 Norway
- 13.3.15 Finland
- 13.3.16 Rest Of Europe
- 13.4 Asia Pacific
- 13.4.1 Japan
- 13.4.2 China
- 13.4.3 South Korea
- 13.4.4 India
- 13.4.5 Australia
- 13.4.6 New Zealand
- 13.4.7 Singapore
- 13.4.8 Thailand
- 13.4.9 Malaysia
- 13.4.10 Vietnam
- 13.4.11 Taiwan
- 13.4.12 Indonesia
- 13.4.13 Philippines
- 13.4.14 Rest Of Asia-pacific
- 13.5 South America
- 13.5.1 Brazil
- 13.5.2 Argentina
- 13.5.3 Rest Of South America
- 13.6 Middle East And Africa
- 13.6.1 South Africa
- 13.6.2 Saudi Arabia
- 13.6.3 Bahrain
- 13.6.4 U.A.E.
- 13.6.5 Kuwait
- 13.6.6 Oman
- 13.6.7 Qatar
- 13.6.8 Egypt
- 13.6.9 Israel
- 13.6.10 Rest Of Middle East And Africa
- 14 Global Exocrine Pancreatic Insufficiency (Epi) Therapeutics And Diagnostics Market: Company Landscape
- 14.1 Company Share Analysis: Global
- 14.2 Company Share Analysis: North America
- 14.3 Company Share Analysis: Europe
- 14.4 Company Share Analysis: Asia-pacific
- 15 Swot Analysis
- 16 Company Profile
- 16.1 Abbvie Inc.
- 16.1.1 Company Snapshot
- 16.1.2 Revenue Analysis
- 16.1.3 Company Share Analysis
- 16.1.4 Product Portfolio
- 16.1.5 Recent Development
- 16.2 Abbott
- 16.2.1 Company Snapshot
- 16.2.2 Revenue Analysis
- 16.2.3 Company Share Analysis
- 16.2.4 Product Portfolio
- 16.2.5 Recent Development
- 16.3 Nestle
- 16.3.1 Company Snapshot
- 16.3.2 Revenue Analysis
- 16.3.3 Company Share Analysis
- 16.3.4 Product Portfolio
- 16.3.5 Recent Developments
- 16.4 Laboratory Corporation Of America Holdings (2022)
- 16.4.1 Company Snapshot
- 16.4.2 Revenue Analysis
- 16.4.3 Company Share Analysis
- 16.4.4 Product Portfolio
- 16.4.5 Recent Development
- 16.5 Janssen Global Services, Llc
- 16.5.1 Company Snapshot
- 16.5.2 Revenue Analysis
- 16.5.3 Company Share Analysis
- 16.5.4 Product Portfolio
- 16.5.5 Recent Development
- 16.6 Alcresta Therapeutics, Inc.
- 16.6.1 Company Snapshot
- 16.6.2 Company Share Analysis
- 16.6.3 Product Portfolio
- 16.6.4 Recent Development
- 16.7 Bioserv Diagnostics Gmbh
- 16.7.1 Company Snapshot
- 16.7.2 Product Portfolio
- 16.7.3 Recent Development
- 16.8 Cilian Ag
- 16.8.1 Company Snapshot
- 16.8.2 Product Portfolio
- 16.8.3 Recent Development
- 16.9 Chirhoclin
- 16.9.1 Company Snapshot
- 16.9.2 Company Share Analysis
- 16.9.3 Product Portfolio
- 16.9.4 Recent Development
- 16.10 Digestive Care, Inc.
- 16.10.1 Company Snapshot
- 16.10.2 Product Portfolio
- 16.10.3 Recent Development
- 16.11 Eaglebio
- 16.11.1 Company Snapshot
- 16.11.2 Product Portfolio
- 16.11.3 Recent Development
- 16.12 Metagenics Llc
- 16.12.1 Company Snapshot
- 16.12.2 Product Portfolio
- 16.12.3 Recent Development
- 16.13 Nordmark
- 16.13.1 Company Snapshot
- 16.13.2 Company Share Analysis
- 16.13.3 Product Portfolio
- 16.13.4 Recent Development
- 16.14 Organon Group Of Companies.
- 16.14.1 Company Snapshot
- 16.14.2 Revenue Analysis
- 16.14.3 Product Portfolio
- 16.14.4 Recent Development
- 16.15 Schebo Biotech Ag
- 16.15.1 Company Snapshot
- 16.15.2 Product Portfolio
- 16.15.3 Recent Development
- 16.16 Vivus Llc
- 16.16.1 Company Snapshot
- 16.16.2 Company Share Analysis
- 16.16.3 Product Portfolio
- 16.16.4 Recent Development
- 17 Questionnaire
- 18 Related Reports 160
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook